SGP vs SKYE

SpyGlass Pharma, Inc. vs Skye Bioscience, Inc. — Valuation Comparison 2026

SGP

Biotechnology
SpyGlass Pharma, Inc.
Quality
5.0
out of 10
Value Trap
Price
$19.84
Last close
Models
7/13
Active
VS

SKYE

Biotechnology
Skye Bioscience, Inc.
Quality
3.6
out of 10
Value Trap
30
LOW
Price
$0.85
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType SGP Fair ValueSGP Upside SKYE Fair ValueSKYE Upside
Bayesian DCF Intrinsic $5.82 -70.7% $0.21 -74.8%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $2.00 -89.9% $1.84 +116.7%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for SGP vs SKYE — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

SGP vs SKYE — Which Stock Is More Undervalued?

SGP scores higher with a 5.0/10 quality rating vs SKYE's 3.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing SpyGlass Pharma, Inc. (SGP) and Skye Bioscience, Inc. (SKYE) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

SGP currently trades at $19.84 with a QOC of 5.0/10, while SKYE trades at $0.85 with a QOC of 3.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).